Invivyd Stock Quote IVVD - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

0.798

Bid

0.77

Ask

0.798

Volume

786,361

0.7723 Day's Range 0.8366

0.3546 52 Week Range 2.74

Market Cap

95.729M

Previous Close

0.8468

Open

0.829

Last Trade

0.7979

Last Trade Time

Financial Volume

$ 625,025

VWAP

0.794832

Average Volume (3m)

2,003,234

Shares Outstanding

119,961,445

Dividend Yield

PE Ratio

-0.56

Earnings Per Share (EPS)

-1.42

Revenue

25.38M

Net Profit

-169.93M

Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and ... Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease which has demonstrated clinically meaningful results in global Phase 3 clinical trials against multiple variants of concern for the prevention and treatment of COVID-19. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

invivyd.com

Headquarters

Wilmington, Delaware, USA

Founded

Invivyd Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IVVD. The last closing price for Invivyd was $0.85. Over the last year, Invivyd shares have traded in a share price range of $ 0.3546 to $ 2.74.

Invivyd currently has 119,961,445 shares outstanding. The market capitalization of Invivyd is $101.58 million. Invivyd has a price to earnings ratio (PE ratio) of -0.56.

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Viru

CANOPY assessed pemivibart safety and tolerability, antiviral immunobridging, and exploratory efficacy against...

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA®...

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

FDA acknowledges that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain; the...

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned...

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

WALTHAM, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.132	-14.1935483871	0.93	1.03	0.7724	1139642	0.91875366	CS
4	0.0962	13.7076090054	0.7018	1.06	0.7002	1896915	0.86445872	CS
12	0.0348	4.55974842767	0.7632	1.09	0.46	2003234	0.70822383	CS
26	0.198	33	0.6	2.74	0.3546	8481614	1.22632468	CS
52	-0.852	-51.6363636364	1.65	2.74	0.3546	4451483	1.21061237	CS
156	-3.902	-83.0212765957	4.7	5.195	0.3546	1964332	1.53079597	CS
260	-3.902	-83.0212765957	4.7	5.195	0.3546	1964332	1.53079597	CS

IVVD - Frequently Asked Questions (FAQ)

What is the current Invivyd share price?

The current share price of Invivyd is $ 0.798

How many Invivyd shares are in issue?

Invivyd has 119,961,445 shares in issue

What is the market cap of Invivyd?

The market capitalisation of Invivyd is USD 101.58M

What is the 1 year trading range for Invivyd share price?

Invivyd has traded in the range of $ 0.3546 to $ 2.74 during the past year

What is the PE ratio of Invivyd?

The price to earnings ratio of Invivyd is -0.56

What is the cash to sales ratio of Invivyd?

The cash to sales ratio of Invivyd is 3.73

What is the reporting currency for Invivyd?

Invivyd reports financial results in USD

What is the latest annual turnover for Invivyd?

The latest annual turnover of Invivyd is USD 25.38M

What is the latest annual profit for Invivyd?

The latest annual profit of Invivyd is USD -169.93M

What is the registered address of Invivyd?

The registered address for Invivyd is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801

What is the Invivyd website address?

The website address for Invivyd is invivyd.com

Which industry sector does Invivyd operate in?

Invivyd operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Symbol	Price	Vol.
RBNERobin Energy Ltd	$ 13.85 (313.43%)	101.81M
OPOceanPal Inc	$ 1.63 (125.45%)	80.28M
LGHLWLion Group Holding Ltd	$ 0.0052 (116.67%)	6.87M
NEONNeonode Inc	$ 16.83 (68.47%)	4.78M
ICONIcon Energy Corporation	$ 2.90 (62.01%)	59.04M
SBETSharpLink Gaming Inc	$ 9.2275 (-71.63%)	41.92M
AIHSSenmiao Technology Ltd	$ 0.381 (-63.01%)	16.8M
CHSNChanson International Holding	$ 0.22 (-60.00%)	15.15M
KWMK Wave Media Ltd	$ 2.91 (-50.43%)	2.59M
JZXNJiuzi Holdings Inc	$ 1.56 (-46.39%)	2.24M
HCTIHealthcare Triangle Inc	$ 0.0201 (-33.00%)	856.89M
GNLNGreenlane Holdings Inc	$ 0.0101 (-34.42%)	792.34M
CGBSCrown LNG Holdings Ltd	$ 0.1104 (31.43%)	788.42M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	$ 12.655 (3.81%)	246.13M
NVDANVIDIA Corporation	$ 141.97 (-2.09%)	180.81M

Symbol

Price

Vol.

HCTIHealthcare Triangle Inc

$ 0.0201

(-33.00%)

856.89M

GNLNGreenlane Holdings Inc

$ 0.0101

(-34.42%)

792.34M

CGBSCrown LNG Holdings Ltd

$ 0.1104

(31.43%)

788.42M

TSLLDirexion Daily TSLA Bull 2X Trust ETF

$ 12.655

(3.81%)

246.13M

NVDANVIDIA Corporation

$ 141.97

(-2.09%)

180.81M

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Invivyd Inc (IVVD) Quote

Invivyd Inc (IVVD)

Professional-Grade Tools, for Individual Investors.

Key stats and details

About Invivyd Inc

Ask ADVFN Intelligence (AI)

IVVD Latest News

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Viru

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Form 8-K - Current report

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Form 8-K - Current report

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Viru

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Form 8-K - Current report

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

IVVD - Frequently Asked Questions (FAQ)

Movers

IVVD Discussion

Your Recent History

Company

Business

Popular

Get The App

Sign in

Go Ad-Free